SeD starts advanced research new universal drug platform

SeD starts advanced research on new universal drug platform

6:16 AM, 23rd May 2017
SeD starts advanced research on new universal drug platform
Drugs to combat a range of diseases including Alzheimer's, diabetes and cancer. (File photo)

SINGAPORE: Singapore eDevelopment Ltd (SeD), through its subsidiary Global BioLife Inc, has started advanced research on a new universal therapeutic drug platform known as Linebacker, to battle a range of diseases including Alzheimer's, diabetes and cancer. The research will be led by two-time Nobel Prize nominee Daryl Thompson.

SeD said that Thompson would leverage his skills in organic and carbohydrate chemistry and the use of pandemic technology in fighting the Ebola virus in the development of Linebacker. Unlike traditional approaches to curing individual diseases with specific drugs, the Linebacker platform seeks a breakthrough option for multiple diseases to be cured. It can also potentially fight drug-resistant viruses and antibiotic-resistant bacteria.

Thompson was chosen for a Nobel Prize in 2015 and 2016 for his research in cutting-edge organic and carbohydrate chemistry as well his research in pandemics technology to fight pandemics such as Ebola. He has used his skill to start research regarding universal therapeutics to cure the world's deadliest diseases. Scott Truesdell, research coordinator and special projects leader at Global BioLife, will perform the research on the Linebacker platform.

Global BioLife has involved Charles River Laboratories International Inc, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

"We expect to get validating laboratory data from the universal therapeutic drug platform within the first six months and are targeting for the platform itself to be done within twelve months. We have a unique patented technology and are already getting interested from Big Pharma players and venture capitalists. This interest will rise as the validating data becomes available," said Thompson.

"Global BioLife recognises the need for affordable cures to emerging pandemics and we will leverage the team's deep expertise to develop this new universal therapeutic drug platform," said Dr Tang Peihong, director and CEO of Global BioLife.

© Worldofchemicals News 



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Clariant, Huntsman merger to create speciality chemicals giant

MUTTENZ, SWITZERLAND: Clariant (CLN) and Huntsman Corporation (HUN) said that they have approved a definitive agreement to combine in a merger of equa ...

Read more
ExxonMobil, Sabic conducts study for proposed US petrochemical project

RIYADH, Saudi Arabia: Affiliates of ExxonMobil Corporation (XOM) and Sabic has signed an agreement to conduct a detailed study of the proposed Gu ...

Read more
Dow inks deals for coatings, silicones investments in Saudi Arabia

MIDLAND, US: The Dow Chemical Company (DOW) has signed two agreements to advance the company’s strategic, innovation agenda in the Kingdom of Sa ...

Read more
PPG, Vision Systems to develop aircraft window shading solutions

SYLMAR, US/ BRIGNAIS, FRANCE: PPG Industries Inc (PPG) and Vision Systems have reached a commercial agreement to develop new applications utilising Vi ...

Read more
IMCD to acquire speciality chemicals business of Bossco

ROTTERDAM, THE NETHERLANDS: IMCD NV has signed an agreement to acquire the speciality chemicals distribution business of Bossco Industries Inc. Bossc ...

Read more
Lubrizol appoints new CSO; makes leadership changes

CLEVELAND, US: The Lubrizol Corporation announced the following changes to its senior leadership team, all effective on 1 June 2017. Bob Graf, curren ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X